iTeos Therapeutics to wind down operations after terminating belrestotug program and GSK collaboration

iTeos Therapeutics, Inc.

Will wind down operations; expects severance charges of $21.8M-$24.7M and other program wind-down costs of $11.1M.
Exploring potential asset sales including EOS-984, EOS-215, and preclinical obesity program targeting ENT1.
Wind down substantially complete in Q3 2025; clinical development programs to wind down thereafter.
Amended employment agreements for CEO, COO, CMO with enhanced severance if terminated during change in control (excluding dissolution).

item 2.05item 5.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.